UOC
HZNP

UBS O'Connor’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

UBS O'Connor’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,664,245
Closed -$887M – 669
2023
Q3 		$887M Buy
7,664,245
+3,332,978
+77% +$358M 15.77% 2
2023
Q2 		$445M Buy
4,331,267
+338,535
+8% +$35.7M 9.38% 1
2023
Q1 		$434M Buy
3,992,732
+1,706,942
+75% +$189M 10.3% 1
2022
Q4 		$260M Buy
2,285,790
+2,211,443
+2,974% +$184M 4.8% 3
2022
Q3 		$4.6M Sell
74,347
-5,000
-6% -$349K 0.05% 324
2022
Q2 		$6.33M Buy
79,347
+54,347
+217% +$5.15M 0.07% 179
2022
Q1 		$2.63M Buy
+25,000
New +$2.44M 0.03% 457
2016
Q2 		– Sell
-195,500
Closed -$3.24M – 551
2016
Q1 		$3.24M Buy
195,500
+121,474
+164% +$2.13M 0.03% 285
2015
Q4 		$1.6M Sell
74,026
-94,774
-56% -$1.84M 0.01% 344
2015
Q3 		$3.35M Buy
+168,800
New +$5.33M 0.03% 322
2013
Q3 		– Sell
-120,000
Closed -$295K – 613
2013
Q2 		$295K Buy
+120,000
New +$288K 0.01% 443

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

UBS O'Connor's HZNP Position: Q4 2023 in Review

UBS O'Connor sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 7,664,245 shares — an estimated $887M sold.

UBS O'Connor first reported a position in HZNP in Q2 2013 and held it in 11 quarters. The position peaked at $887M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • UBS O'Connor reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • UBS O'Connor sold 7,664,245 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $887M.
  • UBS O'Connor first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 11 quarters.
  • UBS O'Connor's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $887M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.